Soltis Investment Advisors LLC Sells 34 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Soltis Investment Advisors LLC lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 677 shares of the biopharmaceutical company’s stock after selling 34 shares during the quarter. Soltis Investment Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $482,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of REGN. International Assets Investment Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 86,013.3% in the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after acquiring an additional 879,916 shares during the period. Worldquant Millennium Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $127,489,000. KBC Group NV boosted its position in shares of Regeneron Pharmaceuticals by 296.7% in the fourth quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company’s stock valued at $97,338,000 after acquiring an additional 102,198 shares during the period. Icon Wealth Advisors LLC boosted its position in shares of Regeneron Pharmaceuticals by 18,342.0% in the third quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock valued at $79,874,000 after acquiring an additional 75,569 shares during the period. Finally, State Street Corp boosted its position in shares of Regeneron Pharmaceuticals by 1.3% in the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock valued at $5,153,603,000 after acquiring an additional 61,277 shares during the period. 83.31% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on REGN shares. Wells Fargo & Company reduced their price objective on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research report on Friday, January 10th. Oppenheimer cut their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. Bank of America restated an “underperform” rating and issued a $565.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. TD Cowen cut their target price on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a research note on Tuesday, February 4th. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $690.36 on Tuesday. The stock’s fifty day moving average is $715.81 and its 200-day moving average is $909.02. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 4.73. The stock has a market capitalization of $75.86 billion, a PE ratio of 18.03, a PEG ratio of 2.38 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a 52 week low of $642.00 and a 52 week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $11.86 earnings per share. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 36.67 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.51%. The ex-dividend date is Thursday, February 20th.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.